phenyl}acetyloxymethyl)-2-phenylmalonate], a novel intestine-specific MTP inhibitor, on food intake, gastric emptying and gut peptides using Sprague-Dawley rats fed 3.1% fat, 13% fat or 35% fat diets. JTT-130 treatment suppressed cumulative food intake and gastric emptying in rats fed a 35% fat diet, but not a 3.1% fat diet. In rats fed a 13% fat diet, JTT-130 treatment decreased cumulative food intake, but not gastric emptying. Also, the treatment with orlistat, a lipase inhibitor, completely abolished the reduction of food intake and gastric emptying by JTT-130 in rats fed a 35% fat diet. On the other hand, JTT-130 treatment increased the plasma concentrations of gut peptides, peptide YY (PYY) and glucagon-like peptide-1 (GLP-1) but not cholecystokinin, in the portal vein in rats fed a 35% fat diet. These elevations in PYY and GLP-1 were also abolished by the treatment with orlistat. Furthermore, JTT-130 treatment in
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Introduction
It has been shown that both oral and duodenal administration of fat suppresses hunger and decreases subsequent energy intake (Chapman et al., 1999; Pilichiewicz et al., 2006) .
Lipase-catalyzed hydrolysis of triglycerides to free fatty acids has been shown to be required for the satiety effects of ingested fat (Feinle et al., 2003; O'Donovan et al., 2003) . These studies
show that the ingestion of fat triggers suppression of food intake, in which digestion and absorption of fat have been known to play an important role. Free fatty acids have been shown to be involved in the suppression of food intake via gut peptides such as PYY, GLP-1 and cholecystokinin (CCK) synthesized by specific enteroendocrine cells located in the epithelium of the intestine (Chaudhri et al., 2006) . PYY and GLP-1 are produced primarily by L cells in the distal small intestine and colon. CCK is secreted from a population of mucosal endocrine I-cells in the proximal intestine. Peripheral injection of exogenous PYY was reported to reduce food intake in rats and human by its action at the Y2 receptor subtype (Batterham et al., 2002) .
Peripheral administration of GLP-1 has been known to reduce food intake in human and other animals (Donahey et al., 1998; Flint et al., 1998; Verdich et al., 2001) . Treatment with This article has not been copyedited and formatted. The final version may differ from this version.
JPET Fast Forward. Published on December 7, 2010 as DOI: 10.1124 at ASPET Journals on December 31, 2017 jpet.aspetjournals.org Downloaded from exogenous CCK or CCK-related peptides reduced food intake in rats or humans (Gibbs et al., 1973; Kissileff et al., 1981) .
The microsomal triglyceride transfer protein (MTP) has been known to take part in the mobilization and secretion of triglyceride-rich lipoproteins from enterocytes and hepatocytes (Xie et al., 2006) . In particular, enteric MTP plays a critical role in the absorption of dietary lipids such as fat and cholesterol (Xie et al., 2006) . Recently, we have developed an novel intestine-specific MTP inhibitor, JTT-130, which is designed to be rapidly catabolized to inactive metabolites immediately after its absorption from the intestine, in order to avoid the inhibition of hepatic MTP resulting in hepatic steatosis (Mera et al., in press) . In previous reports, we demonstrated that JTT-130 suppresses the absorption of dietary fat and cholesterol in the intestine and lowers plasma triglycerides and cholesterol concentrations without accumulation of hepatic triglycerides (Aggarwal et al., 2005; Mera et al., in press ).
It is known that fat absorption in the intestine where MTP plays a pivotal role is a key step in (Wren et al., 2007) . In this study, we examined the effects of JTT-130, an intestine-specific MTP inhibitor, on food intake in Sprague-Dawley rats. In addition, to investigate the characteristics of satiety effects of JTT-130, we evaluated the effects of JTT-130 on gastric emptying and the circulating gut peptides, PYY, GLP-1 and CCK. In order to reveal the effects of dietary fat, we used rats fed diets containing different percentage of fat (3.1%, 13%, and 35 %). Furthermore, to examine the contribution of lipase-catalyzed hydrolysis of triglycerides to free fatty acids, we evaluated these effects of JTT-130 in the presence of a lipase inhibitor, orlistat, also known as tetrahydrolipstatin (Hadvary et al., 1988) .
This article has not been copyedited and formatted. The final version may differ from this version. Japan) . All other reagents used in this study were obtained commercially.
Animals and diets
Male Sprague-Dawley rats (5 weeks) were obtained from Charles River Japan Inc. (Yokohama, Japan) and maintained at a room temperature of 23 ± 3°C and an air humidity of 55 ± 15% in a 12-/12-h light/dark cycle (lights on at 10:00 PM; lights off at 10:00 AM). They were given free access to water and the experimental diets (Table 1) . The diets were a 3.1% fat diet, a 13% fat diet and a 35% fat diet obtained from Oriental Yeast Co. (Osaka, Japan). All procedures were conducted according to the Japan Tobacco Animal Care Committee's guidelines.
Evaluation of food consumption
Rats were housed in individual cages and fasted for at least 24 h prior to the experiment. The 
Evaluation of gastric emptying
Rats were housed in individual cages and fasted for at least 24 h prior to the experiment. The rats were assigned to vehicle or JTT-130 treatment groups (n=6 or 8 (Hayes et al., 2004) . Briefly, the remaining contents collected from the stomach were dried overnight at 90°C and weighed. The experimental diets were dried under the same condition as above and weighed, in order to estimate the original moisture content of them and thereby calculate the dry matter weights of the ingested diets. Gastric emptying, expressed as grams of dry matter emptied, was determined by the following equation: total dry matter emptied (g) = dry matter of ingested diet (g) -dry matter of stomach content (g).
Evaluation of PYY, GLP-1 and CCK levels in the portal vein
Rats were housed in individual cages and fasted for at least 24 h prior to the experiment. The rats were assigned to vehicle or JTT-130 treatment groups (n=8). Immediately after oral dosing of either vehicle or JTT-130 (10 mg/kg), the rats were given free access to the experimental diets. The rats were anesthetized with diethyl ether and blood samples were collected from the 
Statistical analysis
Data are presented as means ± S.E. Statistical analysis was performed using SAS systems, 
Results
Effects of JTT-130 on Food Intake
The effects of JTT-130, an intestine-specific MTP inhibitor, on food intake were evaluated in Sprague-Dawley rats on 3.1% fat, 13% fat, and 35% fat diets (Table 1) . JTT-130 treatment decreased cumulative food intake for 24 h after dosing in a dose-dependent manner in rats on a 35% fat diet (Fig. 1 ). Significant reductions in the cumulative food intake were observed at 8h or later after JTT-130 treatment at the dosages of 10 and 30 mg/kg. However, the reduction of food intake by JTT-130 was attenuated on lower fat diets (Fig. 2) . Little effect of JTT-130 on cumulative food intake was shown with a 3.1% fat diet (Fig. 2C ). On the other hand, treatment with orlistat, a lipase inhibitor, significantly reversed the suppression of food intake by after 24 h of JTT-130 treatment in rats fed a 35% fat diet (Fig. 3) . In addition, orlistat-treated rats had more food intake than vehicle-treated rats (Fig. 3) .
Effect of JTT-130 on Gastric Emptying
The effects of JTT-130 on gastric emptying were evaluated in rats on a 35% fat diet.
JTT-130-treated rats showed decreased gastric emptying for 4, 8 and 24 h after dosing JTT-130
This article has not been copyedited and formatted. The final version may differ from this version. as compared with vehicle-treated rats (Fig. 4A ). JTT-130 treatment decreased gastric emptying in a dose-dependent manner (Fig. 4B ). Significant reductions in gastric emptying were observed at the dosages of 10 and 30 mg/kg. Like the suppression of food intake, the reduction of gastric emptying by JTT-130 was attenuated on lower fat diets (Fig. 4C ).
Furthermore, we assessed the effects of orlistat on the reduction of gastric emptying by in rats on a 35% fat diet. Orlistat treatment significantly reversed the reduction of food intake by JTT-130 on a 35% diet (Fig. 4D) .
Effects of JTT-130 on Gut Hormones
In order to assess the effects of JTT-130 on gut peptides known to be involved in the regulation of food intake, we measured the plasma levels of PYY, GLP-1 and CCK in the portal vein.
JTT-130 treatment significantly increased plasma levels of PYY in the portal vein at 4 h or later after dosing JTT-130 on a 35% fat diet (Fig. 5A) . Also, JTT-130-treated rats showed higher levels of plasma GLP-1 at 8 h or later after dosing than vehicle-treated rats on the mean-value basis (Fig. 5B ). There was a near-significant elevation (P=0.06) of plasma GLP-1 level 24 h after dosing JTT-130 (Fig. 5B) . elevation of CCK levels, but rather decreased CCK levels in the portal vein compared with vehicle treatment on a 35% fat diet (Fig. 5C) . Meanwhile, on a 3.1% fat diet, treatment with JTT-130 produced no significant effects on plasma PYY, GLP-1 and CCK levels (data not shown).
Additionally, we evaluated whether orlistat can reverse the effects of JTT-130 on gut peptides as well as on food intake and gastric emptying in rats fed a 35% fat diet. As a result, orlistat treatment completely abolished the elevation of plasma PYY and GLP-1 levels by JTT-130 on a 35% fat diet ( Fig. 6A and 6B ). We also found orlistat-treated rats showed lower levels of plasma GLP-1 than vehicle-treated rats (Fig. 6B) . On the other hand, no significant change was observed on CCK levels after treatment with orlistat (Fig. 6C) .
Effects of JTT-130 on lipid levels in the intestinal tissue and luminal content
The effects of JTT-130 on lipid levels in the intestinal tissue were evaluated in rats on a 35% fat diet. JTT-130 treatment significantly increased the triglyceride content in the intestinal tissue at 4, 8 and 24h after JTT-130 dosing in rats on a 35% fat diet (Table 2) (Table 2) . We also measured lipid levels in luminal contents in the intestine of rats on a 35% fat diet. The respective levels of triglyceride, free fatty acid and cholesterol in the luminal contents were significantly elevated in the JTT-130-treatment group (Table 3) .
This article has not been copyedited and formatted. The final version may differ from this version. Several recent reviews describe that the gastrointestinal tract is the largest endocrine organ in the body and many gut peptides have been shown to influence energy intake (Chaudhri et al., 2006; Murphy et al., 2006; Cummings and Overduin, 2007) . The hydrolysis of ingested fat into free fatty acids is involved in the suppression of food intake via several gut peptides. For instance, PYY and GLP-1 are well-known gut peptides secreted in response to free fatty acids from L cells primarily localized in the distal intestine. The administration of exogenous GLP-1 is known to reduce food intake in human and rat (Donahey et al., 1998; Flint et al., 1998; Verdich et al., 2001) . Also, the peripheral administration of exogenous PYY3-36, a bioactive product cleaved off from PYY1-36 by dipeptidyl peptidase-4 (DPP4), is shown to reduce food intake in human and rat (Batterham et al., 2002) . In this study, we found that JTT-130 increased plasma concentrations of PYY and GLP-1 in the portal vein in rats fed a 35% fat diet and, like the suppression of food intake, orlistat treatment completely reversed this elevation of plasma PYY and CCK are known to decrease gastric emptying as well as food intake (Chaudhri et al., 2006; Murphy et al., 2006; Cummings and Overduin, 2007) . In this study, we also found that lipids mainly in the jejunum, in which the MTP is predominantly expressed (Mera et al., in press ). Thus, the elevation of free fatty acid contents resulting from MTP inhibition is predicted to be milder in the proximal intestine where I cells are localized than in the distal intestine where L cell are localized. In addition to this, decreased gastric emptying by JTT-130 is supposed to result in decreased inflow of dietary nutrients such as proteins into the intestine, which are also known to stimulate the release of CCK from I cells (Liddle et al., 1985) .
Consequently, the different localization of endocrine cells for these gut peptides may result in the different responses to JTT-130 treatment.
Orlistat is known to reduce fat absorption by lipase inhibition in the intestine and is used for the treatment of obesity. However, the weight loss due to orlistat treatment is less than expected from the level of suppressed fat absorption, in part due to the attenuation of the acute inhibitory effects of oral fat on food intake (O'Donovan et al., 2003) . In this study, we found orlistat treatment elevated cumulative food intake. Furthermore, our data revealed that GLP-1 levels in the orlistat treatment group were lower than in the vehicle treatment group. It is consistent with Rats were allowed to have free access to a 35% fat diet immediately after dosing JTT-130.
Cumulative food intake was monitored until 24h after JTT-130 dosing. Data are presented as means ± S.E. from six animals. *, p < 0.05; **, p < 0.01 versus vehicle group.
Fig. 2. Effects of dietary fat on the suppression of food intake by JTT-130
JTT-130 was administered orally to rats at a dosage of 10 mg/kg after 24 h food deprivation.
Rats were allowed to have free access to 35% fat (A), 13% fat (B) or 3.1% fat (C) diets immediately after JTT-130 dosing. Cumulative food intake was monitored until 24h after dosing JTT-130. Data are presented as means ± S.E. from six animals. *, p < 0.05; **, p < 0.01 versus vehicle group.
Effects of JTT-130 on cumulative food intake in the presence of orlistat
This article has not been copyedited and formatted. The final version may differ from this version. 
Effects of JTT-130 on gastric emptying
A, JTT-130 was administered orally to rats at a dosage of 10 mg/kg after 24 h food deprivation.
Rats were allowed to have free access to a 35% fat diet immediately after dosing JTT-130. 
Effects of JTT-130 on gut peptides
Rats were allowed to have free access to a 35% fat diet immediately after dosing JTT-130. Effects of JTT-130 on gut peptides in the presence of orlistat JTT-130 was administered orally to rats at a dosage of 10 mg/kg after 24 h food deprivation.
Orlistat, a lipase inhibitor, was administered orally 30 min before dosing JTT-130 at a dosage of 100 mg/kg. Rats were allowed to have free access to a 35% fat diet immediately after This article has not been copyedited and formatted. The final version may differ from this version. JTT-130 was administered orally to rats at a dosage of 10 mg/kg after 24 h food deprivation.
Rats were allowed to have free access to a 35% fat diet immediately after dosing JTT-130. The rats were anesthetized with diethyl ether 8 h after JTT-130 dosing. A segment of jejunum was isolated from each rat. Jejunal lipid levels were measured as described in the Methods section.
Data are presented as means ± S.E. from eight animals. *, p < 0.05; **, p < 0.01 versus vehicle group.
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